Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR Study.
{"title":"Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR Study.","authors":"Hironobu Hoshino, Shinya Katsumata, Akira Hamada, Naoki Haratake, Kyoshiro Takegahara, Shoko Nakasone, Hidenori Kawasaki, Mototsugu Shimokawa, Satoshi Shiono, Junichi Soh, Yasuhisa Ohde","doi":"10.1111/pin.70044","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to clarify the risk factors for recurrence in epidermal growth factor receptor (EGFR) mutated and wild-type lung adenocarcinomas, with a focus on the newly proposed International Association for the Study of Lung Cancer (IASLC) grading system. We enrolled 2106 patients who underwent complete anatomical radical resection and had a known EGFR mutational status and IASLC grade. Patient characteristics and pathological features were analyzed to assess the cumulative incidence of recurrence (CIR). No significant differences were found in the CIR between the EGFR mutated (EGFRm) and wild-type groups. In the EGFRm group, multivariate analysis identified IASLC grade 2, grade 3 (reference: grade 1), pathological stage II/III, lymphatic invasion (ly), vessel invasion (v), and plural invasion as independent risk factors for recurrence. In the wild-type group, IASLC grades 2 and 3, pathological stage II/III, ly, and v were identified as independent risk factors for recurrence. Patients with any independent risk factor had a significantly poorer overall survival and a higher CIR compared with those without a risk factor in both the EGFRm and wild-type groups. The IASLC grading system is a valuable prognostic factor for recurrence in patients with lung adenocarcinoma harboring EGFRm.</p>","PeriodicalId":19806,"journal":{"name":"Pathology International","volume":" ","pages":"451-458"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pin.70044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study aimed to clarify the risk factors for recurrence in epidermal growth factor receptor (EGFR) mutated and wild-type lung adenocarcinomas, with a focus on the newly proposed International Association for the Study of Lung Cancer (IASLC) grading system. We enrolled 2106 patients who underwent complete anatomical radical resection and had a known EGFR mutational status and IASLC grade. Patient characteristics and pathological features were analyzed to assess the cumulative incidence of recurrence (CIR). No significant differences were found in the CIR between the EGFR mutated (EGFRm) and wild-type groups. In the EGFRm group, multivariate analysis identified IASLC grade 2, grade 3 (reference: grade 1), pathological stage II/III, lymphatic invasion (ly), vessel invasion (v), and plural invasion as independent risk factors for recurrence. In the wild-type group, IASLC grades 2 and 3, pathological stage II/III, ly, and v were identified as independent risk factors for recurrence. Patients with any independent risk factor had a significantly poorer overall survival and a higher CIR compared with those without a risk factor in both the EGFRm and wild-type groups. The IASLC grading system is a valuable prognostic factor for recurrence in patients with lung adenocarcinoma harboring EGFRm.
期刊介绍:
Pathology International is the official English journal of the Japanese Society of Pathology, publishing articles of excellence in human and experimental pathology. The Journal focuses on the morphological study of the disease process and/or mechanisms. For human pathology, morphological investigation receives priority but manuscripts describing the result of any ancillary methods (cellular, chemical, immunological and molecular biological) that complement the morphology are accepted. Manuscript on experimental pathology that approach pathologenesis or mechanisms of disease processes are expected to report on the data obtained from models using cellular, biochemical, molecular biological, animal, immunological or other methods in conjunction with morphology. Manuscripts that report data on laboratory medicine (clinical pathology) without significant morphological contribution are not accepted.